Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076378" target="_blank" >RIV/65269705:_____/22:00076378 - isvavai.cz</a>
Result on the web
<a href="https://ashpublications.org/blood/article-abstract/140/3/285/485155/Prospective-comparison-of-outcomes-with?redirectedFrom=fulltext" target="_blank" >https://ashpublications.org/blood/article-abstract/140/3/285/485155/Prospective-comparison-of-outcomes-with?redirectedFrom=fulltext</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood.2022015832" target="_blank" >10.1182/blood.2022015832</a>
Alternative languages
Result language
angličtina
Original language name
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy
Original language description
The hypomethylating agents azacitidine (AZA) and decitabine (DEC) have been backbone therapies for older or unfit patients with newly diagnosed acute myeloid leukemia (AML) as single agents and, more recently, in combination with venetoclax.1-5 Despite being widely used for .15 years, AZA and DEC have not been directly compared in a large randomized trial. Here, we sought to indirectly compare the clinical outcomes with DEC or AZA in this patient population in the context of a large prospective trial. All patients provided signed informed consent.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood
ISSN
0006-4971
e-ISSN
1528-0020
Volume of the periodical
140
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
5
Pages from-to
285-289
UT code for WoS article
000857158800014
EID of the result in the Scopus database
2-s2.0-85134777585